2 days Ago By Defense World Staff
Commonwealth Equity Services LLC bought a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 14,694 shares of the biotechnology company’s stock, valued at approximately $36,000.
A number of other institutional investors have also bought and sold shares of the business. Charles Schwab Investment Management Inc. bought a new position in shares of Aclaris Therapeutics in the fourth quarter worth about $82,000.
Geode Capital Management LLC lifted its holdings in Aclaris Therapeutics by 9.3% in the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock worth $974,000 after purchasing an additional 72,309 shares in the last quarter.
Raymond James Financial Inc. bought a new position in Aclaris Therapeutics in the 4th quarter worth approximately $383,000. Assenagon Asset Management S.
A. grew its holdings in Aclaris Therapeutics by 113.9% during the 4th quarter.
Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company’s stock valued at $985,000 after buying an additional 211,585 shares in the last quarter.
Finally, Peapod Lane Capital LLC bought a new stake in shares of Aclaris Therapeutics during the fourth quarter valued at approximately $1,003,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.
Aclaris Therapeutics Stock PerformanceShares of Aclaris Therapeutics stock opened at $1.15 on Friday. The stock has a market cap of $124.
11 million, a price-to-earnings ratio of -2.21 and a beta of 0.53.
The stock has a 50 day moving average price of $1.80 and a 200-day moving average price of $2.23.
Aclaris Therapeutics, Inc. has a one year low of $0.95 and a one year high of $5.
17. Analysts Set New Price TargetsACRS has been the subject of several research analyst reports. StockNews.
com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. Cantor Fitzgerald started coverage on Aclaris Therapeutics in a research report on Tuesday, March 18th. They set an “overweight” rating for the company.
Scotiabank started coverage on Aclaris Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price on the stock.
Finally, HC Wainwright raised Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 price target for the company in a research note on Monday, December 23rd. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock.
Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.67.
Check Out Our Latest Report on ACRSAbout Aclaris Therapeutics (Free Report)Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Featured ArticlesFive stocks we like better than Aclaris TherapeuticsUsing the MarketBeat Dividend Yield CalculatorJPMorgan is a Buy, if You Can Handle The Volatility Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?United States Steel’s Crash: An Unmissable Buying OpportunityHow to Know Which Cryptocurrency to Buy: A Guide for InvestorsRocket Lab Stock: Weathering the Storm, Time for a Comeback?.
